PharmcoRx Pharmacy Launches Mark Cuban Cost Plus Drug Program Expanding Its In-Pharmacy Offerings
- Expansion of in-pharmacy offerings through the partnership with MCCPDC can potentially increase revenue for PharmcoRx Pharmacy.
- The inclusion in the Team Cuban Card provider network allows PharmcoRx to reach a wider customer base and expand its pharmacy service offerings.
- The partnership with MCCPDC aligns with Progressive Care's mission to make positive contributions to the health of its customers.
- None.
The Mark Cuban Cost Plus Drug Company ("MCCPDC") offers more than 1,000 drugs at their actual acquisition cost plus a transparent
Through its agreement with MCCPDC, PharmcoRx locations will be listed as participating pharmacies in the Team Cuban Card provider directory and will actively market the acceptance of the program to its existing customer base as well as in its network of local clinics and healthcare practices.
Pamela Roberts, Chief Operating Officer of Progressive Care, commented, "Through our inclusion in the Team Cuban Card provider network, we are quickly able to expand our PharmcoRx pharmacy offerings by providing consumers with increased access to medications at a significantly reduced cost. By partnering with organizations such as the Mark Cuban Cost Plus Drug Company and our ongoing initiatives to expand our pharmacy service offerings and reach, we are continuing our mission to make positive contributions to the health of our customers."
"Team Cuban Card users love the convenience of getting their prescriptions locally, same-day, at the same low prices they've come to expect from Cost Plus Drugs," said Dr. Alex Oshmyansky, co-founder and CEO of Cost Plus Drugs. "We're excited to add PharmcoRx as an option for consumers."
About PharmcoRx Pharmacy
Progressive Care Inc. (OTCQB: RXMD) through its subsidiaries, is a
Forward-Looking Statements
Forward-Looking Statements contained herein that are not based upon current or historical fact are forward-looking in nature and constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements reflect the Company's expectations about its future operating results, performance, and opportunities that involve substantial risks and uncertainties. These forward-looking statements are based on information currently available to the Company and are subject to a number of risks, uncertainties, and other factors that could cause the Company's actual results, performance, prospects, and opportunities to differ materially from those expressed in, or implied by, these forward-looking statements.
Investor Contact for Progressive Care Inc.:
Michael Glickman
MWGCO, Inc.
917-397-2272
mike@mwgco.net
View original content to download multimedia:https://www.prnewswire.com/news-releases/pharmcorx-pharmacy-launches-mark-cuban-cost-plus-drug-program-expanding-its-in-pharmacy-offerings-301997547.html
SOURCE Progressive Care, Inc.
FAQ
What is the expansion announced by PharmcoRx Pharmacy, a subsidiary of Progressive Care Inc (RXMD)?
What is the Mark Cuban Cost Plus Drug Company's program and how does it benefit patients?
How will PharmcoRx locations benefit from the agreement with MCCPDC?
Who commented on the expansion of PharmcoRx Pharmacy's offerings?